Pharmacological Targeting of Glucagon and Glucagon-Like Peptide 1 Receptors Has Different Effects on Energy State and Glucose Homeostasis in Diet-Induced Obese Mice
暂无分享,去创建一个
Katherine A. Winters | L. Boros | R. Lindberg | M. Véniant | W. Gu | R. Komorowski | Glenn Sivits | Hai Yan | D. Lloyd | Melissa Graham | Narumol Chinookswong
[1] Katherine A. Winters,et al. Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor. , 2010, American journal of physiology. Endocrinology and metabolism.
[2] A. Opipari,et al. Characterization of the metabolic phenotype of chronically activated lymphocytes , 2010, Lupus.
[3] Katherine A. Winters,et al. Long-Term Inhibition of the Glucagon Receptor with a Monoclonal Antibody in Mice Causes Sustained Improvement in Glycemic Control, with Reversible α-Cell Hyperplasia and Hyperglucagonemia , 2009, Journal of Pharmacology and Experimental Therapeutics.
[4] S. Woods,et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. , 2009, Nature chemical biology.
[5] Gregory Stephanopoulos,et al. Effect of Anaplerotic Fluxes and Amino Acid Availability on Hepatic Lipoapoptosis* , 2009, The Journal of Biological Chemistry.
[6] Katherine A. Winters,et al. Fully Human Monoclonal Antibodies Antagonizing the Glucagon Receptor Improve Glucose Homeostasis in Mice and Monkeys , 2009, Journal of Pharmacology and Experimental Therapeutics.
[7] Jason K. Kim,et al. Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice , 2009, Diabetes.
[8] Katherine A. Winters,et al. Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity. , 2008, Journal of medicinal chemistry.
[9] L. B. Knudsen,et al. Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not , 2007, Diabetes.
[10] D. Drucker,et al. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.
[11] C. Kahn,et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. , 2005, The Journal of clinical investigation.
[12] B. Monia,et al. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. , 2004, Diabetes.
[13] L. Boros,et al. GLP-1 stimulates glucose-derived de novo fatty acid synthesis and chain elongation during cell differentiation and insulin release Published, JLR Papers in Press, June 1, 2003. DOI 10.1194/jlr.M300093-JLR200 , 2003, Journal of Lipid Research.
[14] I. Valverde,et al. Cell signalling of the GLP-1 action in rat liver , 2003, Molecular and Cellular Endocrinology.
[15] Bei B. Zhang,et al. Glucagon and regulation of glucose metabolism. , 2003, American journal of physiology. Endocrinology and metabolism.
[16] Marta Cascante,et al. Metabolic profiling of cell growth and death in cancer: applications in drug discovery. , 2002, Drug discovery today.
[17] J. Holst,et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study , 2002, The Lancet.
[18] S. Bonner-Weir,et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.
[19] S. Rössner,et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. , 1999, International Journal of Obesity.
[20] Marta Cascante,et al. Mass isotopomer study of the nonoxidative pathways of the pentose cycle with [1,2-13C2]glucose. , 1998, American journal of physiology. Endocrinology and metabolism.
[21] A. Astrup,et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. , 1998, The Journal of clinical investigation.
[22] J. Holst,et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. , 1997, American journal of physiology. Endocrinology and metabolism.
[23] N. Greig,et al. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. , 1997, The Journal of clinical investigation.
[24] S. Bassilian,et al. Isotopomer study of lipogenesis in human hepatoma cells in culture: contribution of carbon and hydrogen atoms from glucose. , 1995, Analytical biochemistry.
[25] I. Valverde,et al. Potent glycogenic effect of GLP-1(7–36)amide in rat skeletal muscle , 1994, Diabetologia.
[26] J. Egan,et al. Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. , 1994, Endocrinology.
[27] J. Holst,et al. Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man , 1993, Digestive Diseases and Sciences.
[28] D. Drucker,et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[29] P. Ozand,et al. The effects of insulin and glucagon on ketone-body turnover. , 1984, The Biochemical journal.
[30] C. Gehrke,et al. Complete mass spectra of N-trifluoroacetyl-n-butyl esters of amino acids. , 1977, Journal of chromatography.
[31] G. Klain. In vivo effects of glucagon on fatty acid synthesis in fasted and refed rats. , 1977, The Journal of nutrition.
[32] L. Orci,et al. THE ESSENTIAL ROLE OF GLUCAGON IN THE PATHOGENESIS OF DIABETES MELLITUS , 1975, The Lancet.
[33] D. Drucker,et al. Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice. , 2009, Endocrinology.
[34] Jie Zhou,et al. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations , 1999, Diabetologia.
[35] S. Bloom,et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. , 1999, Endocrinology.
[36] S. Bassilian,et al. Mass isotopomer study of glutamine oxidation and synthesis in primary culture of astrocytes. , 1996, Developmental neuroscience.
[37] M. Holness,et al. Glucose utilization by interscapular brown adipose tissue in vivo during nutritional transitions in the rat. , 1991, The Biochemical journal.
[38] P. Ferré,et al. Glucose utilization in vivo and insulin-sensitivity of rat brown adipose tissue in various physiological and pathological conditions. , 1986, The Biochemical journal.